CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Active COVID-19 diseaseWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)

Name (Synonyms) Correlation
drug2 (Standard of Care) SoC Wiki 1.00
drug2067 Remdesivir Wiki 0.26
drug1086 Hydroxychloroquine Wiki 0.10

Correlated MeSH Terms (5)

Name (Synonyms) Correlation
D055371 Acute Lung Injury NIH 0.10
D012127 Respiratory Distress Syndrome, Newborn NIH 0.10
D012128 Respiratory Distress Syndrome, Adult NIH 0.09
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 The Analysis of the Inflammatory Response and the Development of Humoral and Cellular Immunity in Patients With Coronavirus Disease 2019 (COVID-19)

The SARS-CoV-2 infection in the airway epithelium induces cytopathic effects and the cessation of ciliary movement. Increased cytokines and chemokines have been reported to be associated with the severity of the disease. However, most of the molecular and cellular aspects of the inflammatory response and the processes of development of humoral and cellular immunity in these patients are unknown. The aim of this study is characterizing inflammatory processes, seeking to expand the knowledge of the cellular and molecular pathophysiology of COVID-19 that could help in the decision-making of treating health personnel. Mainly, the study is focused on analyzing the inflammatory response by determining cytokines and chemokines. Also, the viral load of the patients with COVID-19 will be determined and will be correlated with the antibody titers. On the other hand, cells will be immunophenotyped to search the cellular depletion profile. Finally, an epidemiological analysis of the patients will be carried out.

NCT04423640 SARS-CoV-2 Other: Active COVID-19 disease

Primary Outcomes

Description: Pg/ml of IL-2, CXCL8 / IL-8,IL-4, CCL5 / RANTES, IL-6, CXCL9 / MIG, IL-10, CCL2 / MCP-1, TNF-alfa, CXCL10 / IP-10, IFN-alfa, soluble receptor IL6, IFN-gamma.

Measure: Serum levels of cytokines and chemokines

Time: Day 0

Description: Pg/ml of IL-2, CXCL8 / IL-8,IL-4, CCL5 / RANTES, IL-6, CXCL9 / MIG, IL-10, CCL2 / MCP-1, TNF-alfa, CXCL10 / IP-10, IFN-alfa, soluble receptor IL6, IFN-gamma.

Measure: Serum levels of cytokines and chemokines

Time: Day 3

Description: Pg/ml of IL-2, CXCL8 / IL-8,IL-4, CCL5 / RANTES, IL-6, CXCL9 / MIG, IL-10, CCL2 / MCP-1, TNF-alfa, CXCL10 / IP-10, IFN-alfa, soluble receptor IL6, IFN-gamma.

Measure: Serum levels of cytokines and chemokines

Time: Day 7

Description: log10 U/ml

Measure: Viral load

Time: Day 0

Description: log10 U/ml

Measure: Viral load

Time: Day 7

Description: Immunophenotypic profile of myeloid cells in COVID by surface molecules CD45, CD14, CD16, mIL-6R, CD73 and CD3. reported in relative fluorescence units and relative percentage of cells analyzed by flow cytometry

Measure: Immunophenotype of myeloid cells

Time: Day 0

Description: Immunophenotypic profile of myeloid cells in COVID by surface molecules CD45, CD14, CD16, mIL-6R, CD73 and CD3. reported in relative fluorescence units and relative percentage of cells analyzed by flow cytometry

Measure: Immunophenotype of myeloid cells

Time: Day 3

Description: Immunophenotypic profile of myeloid cells in COVID by surface molecules CD45, CD14, CD16, mIL-6R, CD73 and CD3. reported in relative fluorescence units and relative percentage of cells analyzed by flow cytometry

Measure: Immunophenotype of myeloid cells

Time: Day 7

Description: relative absorbance units by ELISA

Measure: RBD-SARS-CoV Protein S- antibodies

Time: Day 0

Description: relative absorbance units by ELISA

Measure: RBD-SARS-CoV Protein S- antibodies

Time: Day 3

Description: relative absorbance units by ELISA

Measure: RBD-SARS-CoV Protein S- antibodies

Time: Day 7

Description: Cell count per area (/ mm2) of immune cell sub-populations

Measure: Analysis of cellular immune response

Time: Day 0

Description: Cell count per area (/ mm2) of immune cell sub-populations

Measure: Analysis of cellular immune response

Time: Day 3

Description: Cell count per area (/ mm2) of immune cell sub-populations

Measure: Analysis of cellular immune response

Time: Day 7

Description: Immunophenotypic profile of stem cells and progenitor cells populations COVID by surface molecules CD34, CD38, CD45RA, Lin, CD3, CD8, CD56, CD19, CD20, CD11b, CD235a andCD14. reported in relative fluorescence units and relative percentage of cells, analyzed by flow cytometry

Measure: Hematopoietic stem cells and progenitor cells populations in peripheral blood

Time: Day 0

Description: Immunophenotypic profile of stem cells and progenitor cells populations COVID by surface molecules CD34, CD38, CD45RA, Lin, CD3, CD8, CD56, CD19, CD20, CD11b, CD235a andCD14. reported in relative fluorescence units and relative percentage of cells, analyzed by flow cytometry

Measure: Hematopoietic stem cells and progenitor cells populations in peripheral blood

Time: Day 3

Description: Immunophenotypic profile of stem cells and progenitor cells populations COVID by surface molecules CD34, CD38, CD45RA, Lin, CD3, CD8, CD56, CD19, CD20, CD11b, CD235a andCD14. reported in relative fluorescence units and relative percentage of cells, analyzed by flow cytometry

Measure: Hematopoietic stem cells and progenitor cells populations in peripheral blood

Time: Day 7

Secondary Outcomes

Description: Questionnaire

Measure: Questionnaire of Sociodemographic, labor, pathological and personal characteristics

Time: Day 0

Description: Is used to track a person's status during the stay in an intensive care unit to determine the extent of a person's organ function or rate of failure. The score is based on six different scores, one each for the respiratory, cardiovascular, hepatic, coagulation, renal and neurological systems.

Measure: SOFA (Secuential Organ Failure Assessment Score)

Time: Day 0

Description: Is used to track a person's status during the stay in an intensive care unit to determine the extent of a person's organ function or rate of failure. The score is based on six different scores, one each for the respiratory, cardiovascular, hepatic, coagulation, renal and neurological systems.

Measure: SOFA (Secuential Organ Failure Assessment Score)

Time: Day 3

Description: Is used to track a person's status during the stay in an intensive care unit to determine the extent of a person's organ function or rate of failure. The score is based on six different scores, one each for the respiratory, cardiovascular, hepatic, coagulation, renal and neurological systems.

Measure: SOFA (Secuential Organ Failure Assessment Score)

Time: Day 7

Description: mg/dL

Measure: Fibrinogen

Time: Day 0

Description: mg/dL

Measure: Fibrinogen

Time: Day 3

Description: mg/dL

Measure: Fibrinogen

Time: Day 7

Description: mg/L

Measure: C-Reactive protein

Time: Day 0

Description: mg/L

Measure: C-Reactive protein

Time: Day 3

Description: mg/L

Measure: C-Reactive protein

Time: Day 7

No related HPO nodes (Using clinical trials)